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Breath Holding Spells (BHS) are common in the pediatric population. They are 
paroxysmal non-epileptic events affecting 0.1% to 4.6% of otherwise healthy 
children (1-3). The spells most commonly begin in the first 6 to 12 months of life 
and almost always by 2 years of age. In 90% of children the spells got remission by 
school age and the persistence is extremely rare. There are two types of cyanotic 
and pallid breath holding spells. Some children have both of these spells at some 
time of their lives (1,3,6).




Breath holding spells (BHS) are common paroxysmal non-epileptic events 
in the pediatric population which are very stressfull despite their harmless 
nature. There has been no specific treatment found for the spells yet. The aim 
of this study was to evaluate the efficacy of piracetam (2-oxo-l-pyrrolidine) 
on these children.
Materials & Methods
In this randomized double blind clinical trial study, 150 children with severe 
BHS referred to our pediatric outpatient service were enrolled from August 
2011 to July 2012. The patients were randomized into two equal groups. 
One received 40mg/kg/day piracetam and the other group received placebo, 
twice daily. Patients were followed monthly for three months. The number 
of attacks/month before and after treatment were documented.
Results
Of the enrolled patients, 86 were boys. The mean age of the patients was 
17 months (range, 6 to 24 months). In the piracetam group, 1 month after 
treatment an 81% response to treatment was found. In the placebo group, 
none of the patients had complete remission and 7% of the cases had partial 
remission. Overall, control of breath-holding spells was observed in 91% of 
the patients in the group taking piracetam as compared with 16% in the group 
taking placebo at the end of the study. There was no significant difference 
detected between the groups regarding the prevalence of drug side effects.
Conclusion
A significant difference was detected between piracetam and placebo in 
prevention and controlling BHS. Piracetam (40mg/kg/day) had a good effect 
on our patients.
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identified pallid spells underwent an electrocardiogram 
to exclude a prolonged QT interval. 
Children with the diagnosis of epilepsy, electrolyte 
disturbance, hypoglycemia, iron deficiency anemia, 
impaired kidney function tests, those with abnormal 
neurological findings during examination, those who 
received or were receiving any medications for BHS, or 
those with a doubtful diagnosis were excluded from the 
study. The patients were randomized into two groups of 
75; those receiving piracetam (40mg/kg/day) and those 
receiving placebo, which was similar to the piracetam 
suspension in color and taste, on a randomized basis, 
twice daily for 3months. Follow-up continued until 3 
months after cessation of therapy and no relapse was 
reported after 3 months of therapy and 3 months of 
follow-up.
 Both the patients and the researchers were blind to the 
method of selection and the treatment the groups were 
receiving (double-blinded). The frequency of attacks 
was recorded according to the information given by the 
parents.
The patients attended the clinic at the beginning of the 
study and were then followed monthly for a total period 
of 3 months. The final assessment was carried after 3 
months after inclusion in the study. Typical symptoms 
of BHS were described to the parents of the patients. 
The frequency of attacks was based on the number of 
episodes during that period that had been reported by 
the mother or any other family member taking care of 
the child.
At the end of the three months, the response to treatment 
was evaluated. We defined response as follows: 
1-“Complete response”, the attacks disappeared 
completely, 2-“Partial response; more than 50% 
reduction in the attacks and 3-“No response”; no or less 
than 50% reduction in the attacks. 
The study was registered by the IRCT with IRCT 
ID: IRCT138801231808N1 and was approved by the 
ethical committee of Boo Ali Sina Referral Pediatric 
Hospital. Informed consent was obtained from all the 
parents. Data were collected from the patients in the 
form of a questionnaire which consisted of demographic 
data of the children and some questions including the 
frequency of attacks/month, the type of spells and side 
effects of the drugs. Student’s t-test and Chi-square 
Typically, BHS begins with a series of stereotypic 
movements followed by complete or active exhalation 
which may cause loss of consciousness in the child. 
These reactions may be brought on by pain or by 
strong emotions, such as fear or frustration (2,3). The 
mechanism of BHS yet remains controversial. The 
presence of autonomic imbalance with cerebral anoxia, 
anemia and genetic disorders may be responsible in 
these spells (2,3,6).
No definite therapy has been mentioned for breath 
holding spells in children, although many studies 
have investigated different treatments. Reduction 
in the frequency of spells following treatment with 
iron supplements in cases of iron deficiency anemia, 
atropin in pallid spells and piracetam in repeated 
spells have been reported (4,10,13,15,16). Piracetam 
(2-oxo-l-pyrrolidine) is a cyclic derivative of gamma-
aminobutyric acid (GABA) obtained after the loss of 
one molecule of water followed by ring formation. It 
has been used for various cognitive disorders and BHS 
in children (7,20,21). However, conflicting results and 
few studies on the effect of piracetam in BHS have 
been published in the literature (8-10,14,). This study 
was designed to evaluate the efficacy of piracetam 
compared to placebo in the prevention of severe BHS 
in children.
Materials and Methods
This was a randomized double blind clinical trial study 
on children with severe BHS referred to our pediatric 
outpatient service in the age range of 6 months to 60 
months (5 years) from August 2011 to July 2012.
 Diagnosis of severe BHS was based on the history of 
BHS taken from the parents (three or more spells in 1 
month) before entry into the study protocol, defined by 
the following clinical sequence: provocation followed 
by crying to a point of noiselessness and accompanying 
change of color (cyanotic, or pallid) and ultimately a 
loss of consciousness with an associated alteration in 
body tone (1,2).
Physical examination was performed in all children and 
a detail history about their parents was taken. Blood 
samples were obtained from all patients (CBC, FBS, 
Ca, Mg and renal function tests) and EEG was done to 
exclude patients with seizure disorder. All children with 
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was detected regarding this matter between the two 
groups (p=0.31). 
EEGs were all normal except for 11 patients in which 
slight paroxysmal activity or dysrythmias were 
detected.
One month after treatment with piracetam, response 
to treatment was 81% in the piracetam group (47% 
complete response, 34% partial response) and in 19% 
there was no response. In the placebo group, none of 
the patients had complete response, 7% had partial 
response and 93% no response. Sixty-four percent 
of the piracetam group and 4% of the placebo group 
showed complete response two months after treatment. 
Partial response was seen in 25% of the piracetam 
group and 9% of the placebo group. Eleven percent of 
the piracetam group and 87% of the placebo group had 
no response.
Three months after treatment, complete response was 
seen in 77% of the piracetam group and 6% of the 
placebo group; partial response was seen in 14% and 
10%; and no response was seen in 9% and 84% of 
the patients, respectively. Response to treatment was 
assessed after 3 months in both groups and the results 
are shown in Table 2.
There was no significant difference between types of 
BHS (cyanotic and pallid) and the rate of change after 
treatment in the two groups. The number of attacks/
month, the overall number of attacks/month after 
treatment, rate of change after the first month and the 
whole rate of change for the two groups are shown in 
Figure 1.
The prevalence of drug side effects did not show any 
significant difference between the two groups. In 
children who received piracetam, 2 cases of vomiting 
and 2 cases of emotional liability were seen and in the 
placebo group there were just 2 cases of vomiting and 
no other side effect was detected in the control group.
Discussion
BHS has been reported to occur in approximately 0.1% 
to 4.6% of well children. Most pediatricians agree 
to find out an effective drug despite reassurance for 
prevention of these spells (1,3,4). in this way some 
treatments from Chinese herbal medicine to cardiac 
pacing, antiepileptic and atropine  with variable results 
test were used for statistical evaluation. Wilcoxon 
signed rank test was used to compare the number of 
attacks before and after treatment in each of the studied 
groups; while Mann-Whitney test was used to compare 
the response of treatment between piracetam and the 
placebo groups. The data were analyzed using proper 
statistical test with SPSS 16.0 for Windows. The 
significance level was set at p<0.05.
Results
One-hundred seventy-eight patients were enrolled 
into the study and a total of 28 patients were lost to 
follow-up after treatment and 150 (86 boys, 64 girls) 
completed the study. The ratio of boys to girls was 1.3: 
1. Most of the patients (84%) in the piracetam group 
and (80%) in the placebo group were aged between 6 
and 24 months.
The patients were divided into two groups (A and 
B). At the end of the study, it was found that group 
A were patients receiving piracetam and group B was 
the placebo group. The characteristics of the treatment 
groups are delineated in Table 1.
Frequency of spells varied widely, ranging from 15 per 
day to two per month and the mean frequency was three 
episodes of severe BHS in one week. The duration of 
each spell was difficult to assess with accuracy. Most 
of them were reported to last less than 2 minutes by the 
parents. The number of spells before treatment was not 
different between the groups (p>0.05).
There was no significant difference between the types 
of BHS (cyanotic, pallid and mixed) between the two 
groups. In 110 cases, the spells were cyanotic type; in 
30 cases, pallid; and in 10 children they were mixed 
type.
The provocation factor was not significantly different 
in the two groups (p=0.52); in 91 children it was crying, 
in 34 it was pain, in 15 it was anger and in 10 patients 
it was head bump.
Consanguineous marriages and family history did not 
differ between the two groups (p=0.084).
In 26 children, the parents had a familial relationship 
(nephew and other relationships); 14 children in group 
A and 12 children in group B. A positive family history 
was detected in 12 children in group A and 16 children 
in group B, but no statistically significant difference 
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first months when compared with the second and third 
months. The overall control of BHS was observed in 
91% of the patients (complete  and partial response) in 
the group taking piracetam as compared with 16% in 
the group taking placebo (p<0.05) (Table 2).
Garg (9) has also shown that 2 months piracetam 
therapy reduced the spells significantly and concluded 
that the drug is safe and effective. In the study carried 
out by Aazam et al. (8), the efficacy of piracetam was 
identical (90%) with a relatively higher dose (50-100 
mg/kg/day), but these authors did not have a control 
group for their study. Similar results were obtained 
in the study of Donma et al. (10), in which the spells 
were controlled in 92.3% of the patients treated with 
piracetam and 29.7% of the placebo group patients. 
In a study conducted by Ashrafi et al. (14), piracetam 
in comparison with placebo did not show particular 
advantage. The authors considered the periodic nature 
of these attacks and they emphasized that a response or 
no response in a limited course is not a reliable criterion 
for accepting or rejecting a drug.
Two large scale multicenter studies in children showed 
no serious adverse effects of piracetam; however, 
emotional lability and allergic dermatitis were 
reported occasionally (17,18). In the present study, 
no serious side effects were reported by the parents; 
few, however, vomiting and emotional lability were 
seen in the piracetam and placebo group. No allergic 
reaction, hematological, biochemical, or liver function 
abnormalities were seen.
According to the mechanism of spells, in which the 
extended tissue anoxia will lead to reduction of the 
patients consciousness, it seems piracetam with its 
effect on increasing tissue oxygenation and increasing 
the inhibitory process of tissue hyperpolarization, 
similar to GABA, may be helpful in controlling spells 
(2,3,20,21). 
Some studies showed that attitude problems in the 
mother and the child may trigger spells and with proper 
psychotherapy consultation with the parents, especially 
mothers, these spells may be prevented to a large extent 
(4).
In conclusion, for simple BHS, parental reassurance 
would suffice; however, children with severe and 
repeated BHS should be given piracetam prophylaxis 
have been advised. Some studies have reported the use 
of piracetam in children with BHS (10-13,15).
The age of onset of BHS in most of the studies has 
been in the first 12 months of life. The occurrence of 
breath-holding spells is rare in the first 6 months of life 
and questionable in the neonatal period (1,5,6,). In our 
study, in 78% of the cases, the spells developed at the 
age of 6 to 24 months and the onset of spells in 58% of 
the cases was within the first 12 months of life, which is 
consistent with the above mentioned studies.
The ratio of boys to girls was 1.3:1 which was similar 
to studies conducted by DiMario, Donma and Ashrafi 
et al. (1,10,14).
BHS is provoked by frustration, anger, fear or pain. In 
our study, crying and pain were the common triggering 
factors (84%) and in both groups, cyanotic spells were 
the most common type. These results were in agreement 
with previous reports (1,3,6).
A 20-30% rate of positive familial history in children 
with breath holding spells indicates that genetic may 
be the causality factor for occurrence of these spells 
(1,6,19). In our study, in 28% of the children, the 
parents had a familial relationship and in 18% of the 
children, the parents had a positive familial history of 
BHS.
The frequency of BHS varies from multiple episodes 
per day to as infrequently as on a monthly basis. The 
majority of children; however, experience multiple 
episodes per week. In the study of Di Mario (1) 24/95 
(25%) of the patients experienced more than 1 episode 
per day during peak frequency. In an Indian study 
performed by Bhat et al. (5), only 18% of the patients 
had more than one episode of BHS per day and 64% 
of the patients had multiple episodes occurring every 
week at the time of peak frequency. In our study, only 
24% of the patients had more than one episode of BHS 
per day and 68% of the patients had multiple episodes 
occurring every week at the time of peak frequency. 
This discrepancy may have been caused by iron 
deficiency anemia among patients in the other studies.
In our study, we found significant improvement after 
administration of piracetam, but not after placebo. The 
significant decline in the number of attacks/month after 
administration of piracetam was marked in the second 
and third months, and it was less pronounced in the 
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and piracetam (40mg/kg/day) is a safe and effective drug 
for the treatment of breath-holding spells in children.
Although our center was a referral center and we finally 
had about 150 patients in our study, we recommend this 
study with extended randomized placebo-control trials 
and more duration follow-up, optimal dose and length 
of treatment should be considered to evaluate long-
term benefits and serious side effects of piracetam in 
the prevention of severe BHS.
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Table 2. Response to Treatment in Groups
Response
                                          
group





















64% 25% 11% 77% 14% 9%
Placebo 0% 7% 93% 4% 9% 87% 6% 10% 84%
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